Cite this: *Org. Biomol. Chem.*, 2014, **12**, 8861

Solvent switchable cycloaddition: a (one-pot) metal-free approach towards *N*-substituted benzo[*e*]- or [*f*]isoindolones via C_{sp^2} -H functionalization†

Pratik A. Ambasana,^{a,b} Dipak D. Vachhani,^{*a} Marzia Galli,^{‡a} Jeroen Jacobs,^c Luc Van Meervelt,^c Anamik K. Shah^b and Erik V. Van der Eycken^{*a}

Received 1st August 2014,
Accepted 17th September 2014

DOI: 10.1039/c4ob01644k

www.rsc.org/obc

The tuning of selective ring closure is a nontrivial challenge in synthetic organic chemistry. Herein we report a solvent switchable metal-free [4 + 2] cycloaddition approach via C_{sp^2} -H functionalization. The protocol is highly atom economical with water being the only by-product, delivering *N*-substituted benzo[*e*]- or [*f*]isoindolones in high yields.

The elaboration of methodologies to selectively access heterocycles, while guaranteeing molecular diversity and eco-compatibility, represents a great challenge to organic chemists. In this regard, multi-component reactions (MCR) inherently bequeath molecular diversity and complexity in a single step.¹ Moreover, post-MCR transformations could provide powerful ways to generate libraries of unprecedented molecular skeletons.^{2,3} Employing this strategy, merged with gold-catalyzed dual σ - π activation,⁴ we recently reported a post-Ugi gold-catalyzed regioselective tandem cyclization via C_{sp^3} -H functionalization (Scheme 1).⁵

Stimulated by these findings and our recent endeavours regarding post-Ugi transformations,⁶ we aimed to extend this methodology to the C_{sp^2} -H functionalization employing cascade cyclizations^{4c} of *N*-propynyl phenylpropiolamides to access indenopyridinones (Scheme 1). These compounds are known to possess antihistaminic and antidepressant activity.⁷

According to the literature, cationic gold,^{4c,5} palladium,^{8–10} zinc,¹¹ copper,¹² and iron¹³ have been used alongside phosphorous containing ligands,⁹ Lewis acids and excess of pheno-

Our preceding work⁵

This work

Scheme 1 Different cyclization of *N*-propynyl propiolamides.

Fig. 1 Crystal structure of compound 6a and 7a. Thermal ellipsoids set at 50% probability.¹⁷ Only one molecule is shown for 6a.

^aLaboratory for Organic & Microwave-Assisted Chemistry (LOMAC), Department of Chemistry, University of Leuven (KU Leuven), Celestijnenlaan 200F, B-3001 Leuven, Belgium. E-mail: erik.vandereycken@chem.kuleuven.be, ddvachhani@gmail.com

^bDepartment of Chemistry, Saurashtra University, Rajkot – 360005, India

^cBiomolecular Architecture, Department of Chemistry, University of Leuven (KU Leuven), Celestijnenlaan 200F, B-3001 Leuven, Belgium

†Electronic supplementary information (ESI) available: Experimental procedures, X-ray crystal and spectral data. CCDC 1009249–1009252. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4ob01644k

‡Present address: School of Biological and Chemical Science, Queen Mary University of London, Joseph Priestley Building, Mile End Road, London, E1 4NS, UK.

Table 1 Optimization of the metal-free intramolecular [4 + 2] cycloaddition^a

Entry	Solvent	Temp (°C)	Time (h)	Yield ^b (%)	Ratio (6a:7a) ^b
1	Toluene	120	16 h	71	54 : 46
2	Toluene	140	15 h	76	31 : 69
3	Xylene	140	15 h	73	49 : 51
4	DCE	140	15 h	78	47 : 53
5	Toluene	150	15 h	95	19 : 81
6	Toluene–MeOH (1 : 1)	140	15 h	99	99 : 01
7	iPrOH	140	15 h	99	97 : 03
8	<i>n</i> -BuOH	140	15 h	97 ^c	>99 : 01
9	2,2,2-Trifluoroethanol	140	15 h	95	>99 : 01
10	<i>n</i> -BuOH	140	8 h	98 ^c	>99 : 01
11	<i>n</i> -BuOH	140	3 h	98 ^c	>99 : 01
12	<i>n</i>-BuOH^d	50/140	8 h/3 h	97^c	>99 : 01

^a Unless otherwise stated, all reactions were performed using 0.1 mmol of **5a** in the indicated solvent (1 mL), under N₂ atmosphere and conventional heating. ^b The combined yield and ratio of **6a** and **7a** was estimated on the basis of ¹H NMR analysis using 2,4,6-trimethoxy benzaldehyde as an internal standard (0.1 mmol). ^c Isolated yields. ^d A one-pot sequence was applied using *n*-BuOH as common solvent; for the Ugi-4CR 8 h at 50 °C; followed by 3 h at 140 °C.

Scheme 2 Deuterium labelling experiment with compound **5a**.

lic additives,^{13–15} to catalyze similar intramolecular cyclizations. The access to the precursors for such cyclizations is often rather tedious.^{13,15,16}

To investigate the workability of the concept, *N*-propynyl phenylpropiolamide (**5a**), synthesized *via* Ugi four-component reaction (U-4CR)¹⁷ of *p*-tolualdehyde (**1a**) with propargyl amine (**2a**), 3-phenylpropionic acid (**3a**) and *tert*-butyl isocyanide (**4a**) in methanol, was subjected to our established reaction conditions using 5 mol% of *in situ* generated IPrAuOTf.⁵ To our surprise, we did not observe, by NMR spectroscopy, the desired product. Instead, as revealed by MS-analysis, we observed two other products with similar molecular weight as the starting material. Finally, ¹H NMR and X-ray crystallographic analysis¹⁸ proved that 38% of the benzo[*f*]isoindolone **6a** was furnished,^{4c} next to 36% of the benzo[*e*]isoindolone **7a** (Scheme 1 and Fig. 1). Interestingly, this benzo[*f*]isoindolones are known to act as potent human 17,20-lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC).⁸ Further, a control experiment ruled out the necessity of the metal-catalyst (Table 1, entry 1).

To get some mechanistic insight, a deuterium labelling experiment was performed with compound **5a** (Scheme 2). Use of 2 equiv. of CD₃OD in the reaction resulted in ~87% of deuterium incorporation in the product **6a'**. However, incorporation of deuterium was also observed on the terminal carbon from the propargyl amine part, probably due to facile deprotonation of the terminal acetylene. Based on these observations and previous mechanistical studies,¹⁵ a plausible mechanism with two distinct possibilities is depicted in Scheme 3.

The cyclohexatriene **A**, formed by initial [4 + 2] cyclization, can undergo either isomerization followed by protonation to deliver benzo[*f*]isoindolone **6a**, or a six-electron electrocyclic ring-opening process to afford 1,2-dehydro-[10]annulene **B'**. [1,6]-Electrocyclization of **B'** then leads to cyclic allene **C'**, which upon aromatization, results in the formation of the rearranged benzo[*e*]isoindolone **7a**.

Scheme 3 Plausible mechanism for the metal-free post-Ugi cyclization.

Table 2 Scope of the protocol for the formation of benzo[*e*]isoindolones **6**^{a,b}

One-pot cycloadduct	

^a Unless otherwise stated, all reactions were performed using aldehyde **1** (0.1 mmol), amine **2** (1.05 equiv.), acid **3** (1.05 equiv.) and isonitrile **4** (1.05 equiv.) in *n*-butanol (2 mL) at 50 °C for 8–12 h followed by heating at 140 °C for 3–8 h. ^b Yields are isolated yields. ^c Isolated after chromatographic purification.

Table 3 Scope of the protocol for the formation of rearranged benzo[*f*]isoindolones **7**^{a,b}

Product 7	

^a For U-4CR: all reactions were performed using aldehyde **1** (0.1 mmol), amine **2** (1.05 equiv.), acid **3** (1.05 equiv.) and isonitrile **4** (1.05 equiv.) in *n*-butanol (2 mL) at 50 °C for 8–12 h. ^b For cycloaddition: reactions were run using **5** (0.25 mmol) in dry toluene (2 mL) under N₂ atmosphere at 150 °C for 8–15 h.

Motivated by these findings, we further investigated the conditions to optimize the selective ring closure. Among different solvents screened, toluene was found to be the best, when used at elevated temperature, for the formation of benzo[*e*]isoindolone **7a** (Table 1, entries 2–5). The use of a polar protic solvent solely, or as co-solvent with toluene, dramatically shifts the pendulum towards the formation of benzo[*f*]isoindolone **6a** (Table 1, entries 6–11). To our great satisfaction, an attempt to carry out the sequence in a tandem fashion resulted in an almost quantitative yield with complete selectivity for **6a** (Table 1, entry 12). Besides the atom economy and the catalyst free process, the application of *n*-BuOH also contributes to the green aspect of this protocol.^{19,20}

Having optimized the regioselective cycloadditions (Table 1, entries 5 and 12), we first explored the substrate scope for the one-pot synthesis of benzo[*f*]isoindolones **6**. In most cases, compounds **6** were obtained in excellent yields (84–99%), without the need of further chromatographic purification

(Table 2). Ugi-product resulting from various aromatic aldehydes, isonitriles and acids were well tolerated.

Notably, 2-methylindole-3-carbaldehyde afforded the indolyl-benzo[*f*]isoindolone **6m** in high yield. However, a significant loss of the yield was observed when aliphatic valeraldehyde was used (**6n**, Table 2). The use of phenyl propargylamine failed to give the desired product (**6o**, Table 2).

Next, we turned our attention to generate a small library of rearranged benzo[*e*]isoindolones **7**, employing our optimized conditions (Table 1, entry 5). The reaction proved to be versatile with respect to aldehyde, acid and isonitrile used in the Ugi-reaction, giving the desired compounds **7** in 52–78% yield (Table 3). The presence of an electron withdrawing group on the acid improves the yield of desired product, while the use of an electron deficient aldehyde and electron rich acid lowered the yields (Table 3, **7c**, **d** and **f**). Importantly, employment of Ugi-product **5d**, derived from an *o*-substituted acid, under optimized condition for the formation of rearranged product **7** (Table 1, entry 5), resulted in only one isomer of benzo[*e*]isoindolone **7d** (Table 3, **7d**). The structures of compounds **7** are well characterized by NMR spectroscopy and compounds **7b** and **7d** were also unambiguously assigned by X-ray crystallography (Table 3, entries 3 and 4).¹⁸

Conclusions

We have developed a (one-pot) facile metal-free and atom economical protocol for the synthesis of diversely substituted benzo[*e*]isoindolones **6** and benzo[*f*]isoindolones **7** from readily available starting materials. This one of the rare examples where the selectivity of the ring-closure could be controlled by a simple switch of the solvent.

Acknowledgements

Support was provided by the research fund of the University of Leuven (KU Leuven) and the FWO (Fund for Scientific Research–Flanders, Belgium). PAA is thankful to EXPERTS Asia (Second Cohort) and DDV is thankful to PDM-kort, University of Leuven (KU Leuven) for providing a postdoctoral fellowship. We thank the Hercules Foundation for supporting the purchase of a single crystal diffractometer through project AKUL/09/0035.

Notes and references

- For multicomponent reactions based on isocyanide, see: (a) A. Dömling and I. Ugi, *Angew. Chem., Int. Ed.*, 2000, **39**, 3168; (b) A. Dömling, *Chem. Rev.*, 2006, **106**, 17. For asymmetric multicomponent reactions, see: (c) D. J. Ramón and M. Yus, *Angew. Chem., Int. Ed.*, 2005, **44**, 1602. For multicomponent reactions in general, see: (d) B. Ganem, *Acc. Chem. Res.*, 2009, **42**, 463; (e) L. El Kaïm and L. Grimaud, *Mol. Diversity*, 2010, **14**, 855; (f) E. Ruijter, R. Scheffelaar and R. V. A. Orru, *Angew. Chem., Int. Ed.*, 2011, **50**, 6234; (g) A. Dömling, W. Wang and K. Wang, *Chem. Rev.*, 2012, **112**, 3083; (h) J. Zhu and H. Bienaymé, *Multicomponent Reactions*, Wiley-VCH, Weinheim, 2005; (i) L. Banfi, A. Basso and R. Riva, *Top. Heterocycl. Chem.*, 2010, **23**, 1.
- For gold-catalyzed post-Ugi transformations, see: (a) S. G. Modha, D. D. Vachhani, J. Jacobs, L. Van Meervelt and E. V. Van der Eycken, *Chem. Commun.*, 2012, **48**, 6550; (b) S. G. Modha, A. Kumar, D. D. Vachhani, J. Jacobs, S. K. Sharma, V. S. Parmar, L. Van Meervelt and E. V. Van der Eycken, *Angew. Chem., Int. Ed.*, 2012, **51**, 9572; (c) S. G. Modha, A. Kumar, D. D. Vachhani, S. K. Sharma, V. S. Parmar and E. V. Van der Eycken, *Chem. Commun.*, 2012, **48**, 10916; (d) A. Kumar, Z. Li, S. K. Sharma, V. S. Parmar and E. V. Van der Eycken, *Chem. Commun.*, 2013, **49**, 6803.
- For post-Ugi transformations using transition-metals other than gold see: (a) G. Cuny, M. Bois-Choussy and J. Zhu, *J. Am. Chem. Soc.*, 2004, **126**, 14475; (b) L. El Kaïm, L. Grimaud, X.-F. Le Goff and M. Menes-Arzate, *Chem. Commun.*, 2011, **47**, 8145; (c) D. D. Vachhani, A. Kumar, S. G. Modha, S. K. Sharma, V. S. Parmar and E. V. Van der Eycken, *Eur. J. Org. Chem.*, 2013, 1223; (d) L. Zhang, F. Zhao, M. Zheng, Y. Zhai and H. Liu, *Chem. Commun.*, 2013, **49**, 2894; (e) Z. Xiang, T. Luo, J. Cui, X. Shi, R. Fathi, J. Chen and Z. Yang, *Org. Lett.*, 2004, **6**, 3155; (f) A. D. Piscopio, J. F. Miller and K. Koch, *Tetrahedron*, 1999, **55**, 8189; (g) R. Riva, L. Banfi, A. Basso, V. Cerulli, G. Guanti and M. Pani, *J. Org. Chem.*, 2010, **75**, 5134; (h) F. Bonnaterre, M. Bois-Choussy and J. Zhu, *Org. Lett.*, 2006, **8**, 4351; (i) D. Kadzimirsz, D. Hildebrandt, K. Merz and G. Dyker, *Chem. Commun.*, 2006, 661; (j) L. A. Polindara-García and L. D. Miranda, *Org. Lett.*, 2012, **14**, 5408; (k) W. Erb, L. Neuville and J. Zhu, *J. Org. Chem.*, 2009, **74**, 3109; (l) S. Pandey, S. Khan, A. Singh, H. M. Gaunial, B. Kumar and P. M. S. Chauhan, *J. Org. Chem.*, 2012, **77**, 10211.
- (a) L. Ye, Y. Wang, D. H. Aue and L. Zhang, *J. Am. Chem. Soc.*, 2012, **134**, 31; (b) A. S. K. Hashmi, I. Braun, P. Nösel, J. Schädlich and M. Wietek, *Angew. Chem., Int. Ed.*, 2012, **51**, 4456; (c) A. S. K. Hashmi, M. Wietek, I. Braun, P. Nösel, L. Jongbloed, M. Rudolph and F. Rominger, *Adv. Synth. Catal.*, 2012, **354**, 555.
- D. D. Vachhani, M. Galli, J. Jacobs, L. Van Meervelt and E. V. Van der Eycken, *Chem. Commun.*, 2013, **49**, 7171.
- (a) S. G. Modha, D. D. Vachhani, J. Jacobs, L. Van Meervelt and E. V. Van der Eycken, *Chem. Commun.*, 2012, **48**, 6550; (b) S. G. Modha, A. Kumar, D. D. Vachhani, S. K. Sharma, V. S. Parmar and E. V. Van der Eycken, *Chem. Commun.*, 2012, **48**, 10916; (c) S. G. Modha, A. Kumar, D. D. Vachhani, J. Jacobs, S. K. Sharma, V. S. Parmar, L. Van Meervelt and E. V. Van der Eycken, *Angew. Chem., Int. Ed.*, 2012, **51**, 9572; (d) D. D. Vachhani, A. Kumar, S. G. Modha, S. K. Sharma, V. S. Parmar and E. V. Van der Eycken, *Eur. J. Org. Chem.*, 2013, 1223.

- 7 (a) J. Augstein, A. L. Ham and P. R. Leeming, *J. Med. Chem.*, 1972, **15**, 466; (b) R. Kunstmann and G. Fischer, *J. Med. Chem.*, 1984, **27**, 1312.
- 8 T. Kaku, N. Matsunaga, A. Ojida, T. Tanaka, T. Hara, M. Yamaoka, M. Kusaka and A. Tasaka, *Bioorg. Med. Chem.*, 2011, **19**, 1751.
- 9 Y. Sato, T. Tamura¹, A. Kinbara¹ and M. Mori, *Adv. Synth. Catal.*, 2007, **349**, 647.
- 10 A. C. Childs, G. M. Paul Giblin and M. P. Healy, *PCT Int. Appl*, WO2009019281 A1, 2009.
- 11 H. Yeo, Y. Li, L. Fu, J.-L. Zhu, E. A. Gullen, G. E. Dutschman, Y. Lee, R. Chung, E. S. Huang, D. J. Austin and Y. C. Cheng, *J. Med. Chem.*, 2005, **48**, 534.
- 12 D. Rodríguez, L. Castedo, D. Domínguez and C. Saá, *Synthesis*, 2004, 761.
- 13 R. L. Danheiser, A. E. Gould, R. F. de la Pradilla and A. L. Helgason, *J. Org. Chem.*, 1994, **59**, 5514.
- 14 M. V. Santander, M. B. Pastor, J. N. Nelson, C. Castro and W. L. Karney, *J. Org. Chem.*, 2013, **78**, 2033.
- 15 D. Rodríguez, A. Navarro-Vázquez, L. Castedo, D. Domínguez and C. Saa, *J. Am. Chem. Soc.*, 2001, **123**, 9178.
- 16 Y. Kita, R. Okunaka, T. Honda, M. Kondo, O. Tamura and Y. Tamura, *Chem. Pharm. Bull.*, 1991, **39**, 2106.
- 17 (a) I. Ugi, R. Meyr, U. Fetzer and C. Steinbrucker, *Angew. Chem.*, 1959, **71**, 386; (b) S. Marcaccini and T. Torroba, *Nat. Protoc.*, 2007, **2**, 632.
- 18 CCDC 1009252 (**6a**), CCDC 1009249 (**7a**), CCDC 1009250 (**7b**), CCDC 1009251 (**7d**).[†]
- 19 C. R. Hargreaves and J. B. Manley, <http://www.acs.org/content/dam/acsorg/greenchemistry/industriainnovation/roundtable/solvent-selection-guide.pdf>, January 18, 2014.
- 20 C. Capello, U. Fischer and K. Hungerbühler, *Green Chem.*, 2007, **9**, 927.